Evaluation the Efficacy of Sublingual Squalene for Treatment of COVID-19

Mashhad University of Medical Sciences0 个研究点目标入组 200 人开始时间: 待定最近更新: 2021年11月1日

适应症

试验速览

暂无简介。

•Patient with definite COVID-19 confirmed by molecular or imaging methods in which the oxygen saturation level is less than 93% (SPO2 <93%) and requires respiratory support including oxygen therapy.
•Patient with definite COVID-19 confirmed by molecular or imaging methods with hypotension (systolic pressure less than 90)
•Patient with definite COVID-19 confirmed by molecular or imaging methods with Persistence of dehydration and oral intolerance after outpatient supportive care
•Patient with definite COVID-19 confirmed by molecular or imaging methods who are considered as high risk patient regardless of the clinical symptoms based on the underlying disease, clinical condition, and paraclinical findings. (Uncontrolled high blood pressure, uncontrolled diabetes, obesity, etc.)

•History of myocardial ischemia, heart failure and advanced COPD
•Dissatisfaction of the patient or the patient's companion
•Any mental disability that prevents effective communication
•Existence of any physical disability that prevents one from performing daily activities independently. (Physical disability leads to disability before COVID-19 infection)
•History of alcohol or drug abuse
•Possibility of pregnancy and lactation

发起方